ArticleFrontiers in immunology2026
Allicin inhibits PD-L1 through the IL-6/JAK2/STAT3 pathway to suppress immune evasion in osteosarcoma.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Bone niche-driven antitumor immune failure in osteosarcoma: Mechanisms and therapeutic implications (Review).Oncology letters · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: PD-L1 is one of the most critical immune checkpoint proteins, inhibiting T-cell immune responses by binding to PD-1. This study aims to validate that allicin can regulate PD-L1 expression through the IL-6/JAK2/STAT3 pathway, thereby inhibiting immune evasion in osteosarcoma. Methods: We screened differentially expressed genes associated with prognosis using the GEO database and identified the IL-6/JAK2/STAT3/PDL1 pathway through KEGG and GO enrichment analysis. We established the HOS human osteosarcoma cell line and the K7M2 mouse osteosarcoma cell line. Both cell lines were treated with allicin at concentrations of 12.5, 25, and 50 μmol/L. Transwell, clonogenic, and scratch assays validated allicin's inhibitory effects on osteosarcoma cell growth, migration, and invasion. Western Blot assays measured expression levels of key proteins including IL-6, JAK2, STAT3, PD-L1, and phosphorylated JAK2/STAT3. Animal models were established in Balb/c mice and treated with allicin. Mouse clinical signs, tumor volume, and size were recorded. Tumor microenvironment and immune cell infiltration markers (CD3+, CD4+, CD8+, IFN-γ, granzyme B) were analyzed via flow cytometry and immunofluorescence. Immunofluorescence and immunohistochemistry were employed to detect the expression of PD-L1, CD8, and other relevant markers in mouse tumor models, validating allicin's inhibitory effect on immune evasion. Results: In osteosarcoma cell lines treated with allicin, the IL-6/JAK2/STAT3 signaling pathway was downregulated, and PD-L1 expression was significantly suppressed. In allicin-treated mice, recruitment of CD4+ and CD8+ T cells increased, IFN-γ and granzyme B expression enhanced, and tumor immune evasion was markedly inhibited. Conclusion: Allicin suppresses PD-L1 expression by modulating the IL-6/JAK2/STAT3 signaling pathway, thereby improving the tumor microenvironment and inhibiting immune evasion in osteosarcoma cells. This study demonstrates the potential of allicin as an adjunct to immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.